Aleks Radovic-Moreno

What if a medicine listened to cues from your body to provide therapy when and where it's needed?

Share This Talk

Have a suggestion for The Hive?
Submit a Nomination Today

About Aleks Radovic-Moreno

Aleks Radovic-Moreno, PhD, is on the leadership team of Alivio and is a Vice President at PureTech Health, the parent company of Alivio. He was previously a Research Scientist at the biotech startup, AuraSense Therapeutics (Exicure Inc), where he was a lead inventor of the company's core immunotherapy platform. Dr. Radovic-Moreno completed his graduate work as a NSF Fellow in Robert Langer's lab at MIT, where he developed novel strategies for managing bacterial infections, including a novel vaccine candidate for chlamydia, a disease for which no vaccine currently exists. Dr. Radovic-Moreno was awarded the Alumni Achievement Award by the Pennsylvania State University for extraordinary professional accomplishment by graduates under the age of 35. He received his B.S. in Chemical Engineering from the Pennsylvania State University and PhD in Chemical and Biomedical Engineering from MIT and the Harvard-MIT Division of Health Sciences & Technology.

Find out more

About This Idea

For the millions of people worldwide who suffer when their own immune system turns against them, today’s treatment options—such as systemic steroids and immunosuppressants—are limited or inefficient. Led by co-founder Aleks Radovic-Moreno, Alivio is pioneering a new approach for treating autoimmune and inflammatory diseases based on the concept of targeted immunoregulation. Check out Aleks’s 2017 TEDMED Hive Talk to learn more about Alivio’s novel hydrogel technology and how it can serve as an alternative treatment option for autoimmune and inflammatory diseases. 

Find out more

More Talks from the Hive

These talks are all a part of special session at TEDMED, called "Audacious" where we invite our innovators to take the stage and share the central idea they are working on, in short 2-minute talks. These talks are creatively grouped by 4 mini-segments, that serves as a creative link between each talk. To find out more visit The Hive page.